C4 Therapeutics begins dosing in Phase Ib trial for multiple myeloma

C4 Therapeutics has begun dosing in a Phase Ib study assessing cemsidomide and elranatamab (Elrexfio) in patients with ...
ascopubs.org

A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.

Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...
ascopubs.org

Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy Adult subjects with ...
Yahoo Finance

IRLAB Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson's Disease

GOTHENBURG, NE / ACCESS Newswire / February 26, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company focused on discovering and developing new treatments for Parkinson's disease, today ...
Seeking Alpha

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study ...

- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 ...
Nasdaq

Gabather reports initial positive results from the EEG/fMRI target engagement study

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo ...
Business Wire

Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)

STEVENAGE, England--(BUSINESS WIRE)--Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain ...
Finanznachrichten

IRLAB Therapeutics: IRLAB Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson's Disease

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, NE / ACCESS Newswire / February 26, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a ...